Table 1.
The table shows the cases of skin infections described in the literature according to the search criteria reported in the supplementary files search strategy section.
| Reference | Clinical Condition | Clinical Presentation | Clinical Diagnosis |
Number of Patients (Percentage) |
Body Site | Drugs | Microbiological Identification | Antibiotic Resistance |
|---|---|---|---|---|---|---|---|---|
| Bavaro et al. [7] | Stage IV lung cancer | ND | Skin and soft tissue infection | 2/12 (17%) | ND | Pembrolizumab | methicillin-sensitive Staphylococcus aureus | ND |
| Karam et al. [8] | ND | erysipelas | Skin and soft tissue infection | 7/36 (19.4%) | ND | Anti PD-1/PD-L1 not specified |
ND | ND |
| Fujita et al. [9] | Stage IV lung cancer (non-small cell) | ND | Skin and soft tissue infection | 2/166 (1.2%) | ND | Nivolumab | methicillin-sensitive Staphylococcus aureus | ND |
| Ross et al. [10] | ND | ND | Skin and soft tissue infection | 8/112 (7.2%) | ND | Nivolumab Pembrolizumab Ipilimumab |
1 Actinomyces radingae 1 Enterobacter cloacae 1 Enterococcus faecalis 2 methicillin-resistant Staphylococcus aureus 3 ND bacteria |
Methicillin |
| Tabchi et al. [11] | Stage IV lung cancer (adenocarcinoma) | ecthyma gangrenosum | Skin and soft tissue infection | 1/1 (100%) | right cervical region and torso | Nivolumab | S. aureus | ND |